The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets.

Departamento de Biología Molecular and Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), Universidad Autónoma, Madrid, Spain.
British Journal of Pharmacology (Impact Factor: 5.07). 06/2010; 160(4):821-32. DOI: 10.1111/j.1476-5381.2010.00727.x
Source: PubMed

ABSTRACT GRK2 is a ubiquitous member of the G protein-coupled receptor kinase (GRK) family that appears to play a central, integrative role in signal transduction cascades. GRKs participate together with arrestins in the regulation of G protein-coupled receptors (GPCR), a family of hundreds of membrane proteins of key physiological and pharmacological importance, by triggering receptor desensitization from G proteins and GPCR internalization, and also by helping assemble macromolecular signalosomes in the receptor environment acting as agonist-regulated adaptor scaffolds, thus contributing to signal propagation. In addition, emerging evidence indicates that GRK2 can phosphorylate a growing number of non-GPCR substrates and associate with a variety of proteins related to signal transduction, thus suggesting that this kinase could also have diverse 'effector' functions. We discuss herein the increasing complexity of such GRK2 'interactome', with emphasis on the recently reported roles of this kinase in cell migration and cell cycle progression and on the functional impact of the altered GRK2 levels observed in several relevant cardiovascular, inflammatory or tumour pathologies. Deciphering how the different networks of potential GRK2 functional interactions are orchestrated in a stimulus, cell type or context-specific way is critical to unveil the contribution of GRK2 to basic cellular processes, to understand how alterations in GRK2 levels or functionality may participate in the onset or development of several cardiovascular, tumour or inflammatory diseases, and to assess the feasibility of new therapeutic strategies based on the modulation of the activity, levels or specific interactions of GRK2.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The serotonin 5-HT4 receptor is a member of the superfamily of G-protein-coupled receptors (GPCRs) that mediates many physiological effects in the central nervous system and its periphery. Recently, a 5-HT4 receptor agonist was shown to produce faster antidepressant-like response in animal models in comparison to conventional antidepressants, and this effect persists for at least 2 weeks of treatment without generating tolerance. Importantly, long-term administration of various classes of antidepressants has been reported to induce desensitization and/or downregulation of 5-HT4 receptors in brain areas implicated in the physiopathology of depression. These observations point to the importance of studying the mechanisms of desensitization and regulation of the 5-HT4 receptors since they seem distinctively implicated in therapeutic response to the classical selective serotonin reuptake inhibitors (SSRIs) and novel faster acting antidepressants. Hence, desensitization and internalization mechanisms of the 5-HT4 receptors have been characterized with special emphasis on the 5-HT4a and 5-HT4b isoforms. WIREs Membr Transp Signal 2012, 1:779–788. doi: 10.1002/wmts.52 For further resources related to this article, please visit the WIREs website.
    11/2012; 1(6). DOI:10.1002/wmts.52
  • [Show abstract] [Hide abstract]
    ABSTRACT: G protein-coupled receptor kinase 2 (GRK2) has recently emerged as a negative modulator of insulin signalling. GRK2 downregulation improves insulin sensitivity and prevents systemic insulin resistance (IR). Cardiac GRK2 levels are increased in human heart failure, while genetically inhibiting GRK2 leads to cardioprotection in mice. However, the molecular basis underlying the deleterious effects of GRK2 up-regulation and the beneficial effects of its inhibition in the heart are not fully understood. Therefore, we have explored the interconnections among a systemic IR status, GRK2 dosage and cardiac insulin sensitivity in adult (9month-old) animals. GRK2(+/-) mice display enhanced cardiac insulin sensitivity and mild heart hypertrophy with preserved systolic function. Cardiac gene expression is reprogrammed in these animals, with increased expression of genes related to physiological hypertrophy, while the expression of genes related to pathological hypertrophy or to diabetes/obesity co-morbidities is repressed. Notably, we find that cardiac GRK2 levels increase in situations where IR develops, such as in ob/ob mice or after high fat diet feeding. Our data suggest that GRK2 downregulation/inhibition can help maintain cardiac function in the face of co-morbidities such as IR, diabetes or obesity by sustaining insulin sensitivity and promoting a gene expression reprogramming that confers cardioprotection.
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 09/2014; 1842(12). DOI:10.1016/j.bbadis.2014.09.004 · 5.09 Impact Factor
  • Source

Full-text (2 Sources)

Available from
Jun 5, 2014